The microbial metabolome: remodeling the therapeutic landscape in hematologic malignancies
The gut microbiome's metabolome critically shapes drug efficacy and toxicity in hematologic malignancies. This review explores how microbial metabolites influence chemotherapy, immunotherapy, and transplant outcomes, and how they can be harnessed as biomarkers and therapeutic targets. Moving from association to intervention, we outline a pathway toward metabolome-informed precision oncology, transforming the "second genome" into a actionable ally for improved cancer therapy.
Authors
- Hamed Soleimani Samarkhazan (ORCID: https://orcid.org/0000-0003-1045-7613)
- Rushen Gafarov (ORCID: https://orcid.org/0000-0002-1805-6366)
- Yaseer almajidi
- Liang Zhang
Institutions
- University of Tehran (IR)
- Ganzhou People's Hospital (CN)
- Samarkand State Medical Institute (UZ)
- Shahid Beheshti University of Medical Sciences (IR)
Publication Details
- Journal
- npj Biofilms and Microbiomes
- Published
- 2026-04-21
- DOI
- https://doi.org/10.1038/s41522-026-00972-2
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00